

Andrea True Kelly, PhD

*VP Medical Affairs and
Clinical Development*



Andrea True Kelly, PhD is the Vice President of Medical Affairs and Clinical Development at Altesa. Andrea joined Altesa with over 20 years' experience with biopharmaceutical companies and academic medical centers, specializing in clinical development and operations and medical affairs from first-in-human studies to post-marketing support and outreach. Included in her infectious disease development portfolio are Fuzeon® (enfuvirtide), the first marketed fusion inhibitor for HIV, and Tembexa® (brincidofovir), now approved for the treatment of smallpox. Most recently, she served as a principal consultant with the NDA Group after establishing the clinical development, operations and medical affairs programs at Istari Oncology, in support of a novel immunotherapeutic based on the Sabin type-1 oral poliovirus vaccine.

At Altesa, Dr. Kelly leads the clinical development and operations and works collaboratively with the regulatory and CMC teams, while helping to establish the overall corporate infrastructure to ensure a solid foundation for the expanding clinical programs. Dr. True Kelly earned her PhD in Pharmacology at the University of Illinois Chicago, College of Medicine, and completed her fellowship at the NIH under the Director of the NHLBI, with a focus on vascular biology.